Indonesia Cohort of IO HAT Study to Evaluate Diabetes Management, Control, and Complications in Retrospective and Prospective Periods Among Insulin-Treated Patients with Type 1 and Type 2 Diabetes

Achmad Rudijanto, Made R Saraswati, Em Yunir, Poppy Kumala, Happy HS Puteri, Veny VV Mandang


Background: hypoglycemia is a major adverse event of insulin therapy for diabetes mellitus patients. The study was conducted to evaluate the incidence of hypoglycemia among insulin treated patients with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) in the Indonesian cohort. Methods: this Indonesian cohort study consisted of retrospective and prospective evaluation of hypoglycemic episodes, using International Operations Hypoglycemia Assessment Tool (IO HAT) in 374 patients with diabetes (T1DM; n=17 or T2DM; n=357). The patients of ≥18 years of age and treated with insulin for >12 months were selected for this study ( number: NCT02306681). Results: a total of 374 patients were enrolled in this study and completed SAQ1. All patients with T1DM (17 [100%]), and 347 (97.2%) patients with T2DM completed SAQ2. Almost all the patients in the 4-week prospective period reported at least one hypoglycemic event (T1DM 100%, T2DM 99.4%) and the incidence rate of any hypoglycemia was 67.5 events per patient-year (PPY) and 25.7 events PPY for T1DM and T2DM patients, respectively. Among patients with T1DM and T2DM, 5.9% and 36.4%, respectively, did not know what hypoglycemia was at baseline, also high proportion of patients had impaired hypoglycemic awareness in the study (82.4% and 62.7%, respectively). Conclusion: overall, high proportion of patients reported hypoglycemic events in the prospective period indicating under reporting during the retrospective period due to recall bias. Therefore, there is a need for patient education program to improve the awareness of hypoglycemia in diabetes patient in Indonesia.


International Operations Hypoglycemia Assessment Tool; Hypoglycemia; insulin-treated patients with diabetes; observational; Indonesia


Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.

Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249–57.

International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: IDF; 2015.

Abiola D, Sathyapalan T, Hepburn D. Management of type 1 and type 2 diabetes requiring insulin. Prescriber 2016. 2016;27(9):50-7.

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes. Diabetes Care. 2015;38(1):140–9.

Leiter LA, Boras D, Woo VC. Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals. Can J Diabetes. 2014;38(1):38–44.

Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl. 2009;63(164):6–10.

Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14(5):665–71.

Workgroup on Hypoglycemia American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245–9.

Nakar S, Yitzhaki G, Rosenberg R, et al. Transition to insulin in Type 2 diabetes: family physicians’ misconception of patients’ fears contributes to existing barriers. J Diabetes Complications. 2007;21(4):220–6.

Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab. 2013;98(5):1845-59.

McEwan P, Larsen Thorsted B, Wolden M, et al. Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England. BMJ Open Diabetes Res Care. 2015;3(1): e000057. doi: 10.1136/bmjdrc-2014-000057

Moheet A, Seaquist ER. Hypoglycemia as a driver of cardiovascular risk in diabetes. Curr Atheroscler Rep. 2013;15(9):351.

Soewondo P, Soegondo S, Suastika K, et al. The DiabCare Asia 2008 study – Outcomes on control and complications of type 2 diabetic patients in Indonesia. Med J Indones 2010;19(4):235–44.

Goh S, Hussein Z, Rudijanto A. Review of insulin-associated hypoglycemia and its impact on the management of diabetes in South East Asian countries. Journal of diabetes investigation. doi: 10.1111/jdi.12647/pdf.

Soeatmadji DW, Rosandi R, Sasiarini L. Indonesian guideline of type-2 DM management during Ramadan, 2015.

Widyahening IS, Yolanda van der Graaf, Soewondo P, et al. Awareness, agreement, adoption and adherence to type 2 diabetes mellitus guidelines: a survey of Indonesian primary care physicians. BMC Fam Pract. 2014;15:72. doi:10.1186/1471-2296-15-72

Emral R, Pathan F, Cortes C, et al. Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey of 7289 patients from nine countries. Diabetes Res Clin Pract. 2017; doi:

International Society for Pharmacoepidemiology (ISPE); Guidelines for Good Pharmacoepidemiology Practices (GPP).Initially issued: 1996. Revision 2, April, 2007.

World Medical Association (WMA) Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. 64th WMA General Assembly, Brazil, October 2013.

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-9.

Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev. 2003;19:232-40.

Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: A systematic review and meta-analysis of population based studies. PLoS One. 2015;10(6):e0126427.

Curkendall SM, Zhang B, Oh KS, et al. Incidence and cost of hypoglycemia among patients with type 2 diabetes in the United States: Analysis of a health insurance database. JCOM. 2011;18(10):455-62.

Giorda CB, Ozzello A, Gentile S, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol. 2015;52(5):845-53.

Kalra S, Mukherjee JJ, Venkataraman S, et al. Hypoglycemia: The neglected complication. Indian J Endocrinol Metab. 2013;17:819-34.

Martin Gilmour of the Diabetic Hypoglycemia Editorial Team. Diabetes Treatment Review: Reducing the risk of hypoglycemia with basal insulin analogues. Diabetic Hypoglycemia. 2008;1(1):15-6.

Eliaschewitz FG, Barreto T. Concepts and clinical use of ultra-long basal insulin. Diabetol Met Syndr. 2016;8:2. DOI: 10.1186/s13098-015-0117-1.

Pranoto A, Novida H, Prajitno JH, et al. Safety and efficacy in early insulin initiation as comprehensive therapy for patients with type 2 diabetes in primary health care centers. Acta Med Indones. 2015;47(2):104-10.

Full Text: PDF


  • There are currently no refbacks.